Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

278
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
278

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apadamtase Alfa: First Approval.

Drugs·2024
Same author

Zuranolone: First Approval.

Drugs·2023
Same author

Correction to: Birch Bark Extract: A Review in Epidermolysis Bullosa.

Drugs·2023
Same author

Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.

Drugs·2023
Same author

Birch Bark Extract: A Review in Epidermolysis Bullosa.

Drugs·2023
Same author

Flotufolastat F 18: Diagnostic First Approval.

Molecular diagnosis & therapy·2023
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Related Experiment Video

Updated: Feb 2, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

GP2017: An Adalimumab Biosimilar.

Young-A Heo1

  • 1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 22, 2018
PubMed
Summary
This summary is machine-generated.

GP2017, a biosimilar adalimumab, demonstrated equivalent efficacy, safety, and immunogenicity to reference adalimumab in autoimmune conditions. Switching between the two therapies did not impact clinical outcomes, offering a viable alternative.

More Related Videos

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model
10:11

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model

Published on: March 7, 2013

15.8K
In Vitro Assay to Study Tumor-macrophage Interaction
08:36

In Vitro Assay to Study Tumor-macrophage Interaction

Published on: August 1, 2019

8.0K

Related Experiment Videos

Last Updated: Feb 2, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model
10:11

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model

Published on: March 7, 2013

15.8K
In Vitro Assay to Study Tumor-macrophage Interaction
08:36

In Vitro Assay to Study Tumor-macrophage Interaction

Published on: August 1, 2019

8.0K

Area of Science:

  • Immunology
  • Pharmacology
  • Biotechnology

Background:

  • Adalimumab is a widely used anti-TNF-α antibody for autoimmune inflammatory conditions.
  • The development of biosimilars like GP2017 offers potential for increased patient access and cost-effectiveness.

Purpose of the Study:

  • To evaluate the efficacy, safety, tolerability, and immunogenicity of GP2017, a biosimilar adalimumab.
  • To assess the impact of switching between GP2017 and reference adalimumab on clinical outcomes.

Main Methods:

  • Physicochemical and functional characterization of GP2017 compared to reference adalimumab.
  • Pharmacokinetic studies in healthy volunteers.
  • Clinical trials in patients with plaque psoriasis and rheumatoid arthritis.
  • Assessment of switching scenarios between GP2017 and reference adalimumab.

Main Results:

  • GP2017 exhibited similar physicochemical and functional properties to reference adalimumab.
  • Pharmacokinetic similarity was demonstrated in healthy volunteers.
  • GP2017 showed equivalent clinical efficacy, tolerability, safety, and immunogenicity profiles compared to reference adalimumab in patients.
  • Multiple switches between GP2017 and reference adalimumab did not affect efficacy, tolerability, or immunogenicity.

Conclusions:

  • GP2017 is a clinically effective biosimilar alternative to reference adalimumab for autoimmune inflammatory conditions.
  • Switching between GP2017 and reference adalimumab is feasible without compromising patient outcomes.
  • GP2017 provides a valuable therapeutic option for patients requiring adalimumab treatment.